Tresiba® receives positive opinion from CHMP for treatment of children with diabetes

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1–17 years with diabetes. Once the European Commission approves the licence extension, physicians in the European Union will be able to prescribe insulin degludec to children and adolescents aged 1–17 with type 1 and type 2 diabetes.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Diabetes Endochrine Disorders chmp GLP-1 receptor agonists hypoglycaemia insulin degludec/detemir Latest News Tresiba Source Type: news